Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.26), $0.08 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $28 million versus the consensus estimate of $26.82 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.